Aytu BioPharma Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, Aytu BioPharma stock has a consensus rating of "Strong Buy" and an average price target of $9.50. The average 1-year stock price forecast is 341.86% higher than the current stock price, while the lowest is $7.00 (+225.58%) and the highest is $14.5 (+574.42%).

Price Target: $9.50 (+341.86%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$7.00	$9.50	$7.00	$14.5
Change	+225.58%	+341.86%	+225.58%	+574.42%

Analyst Ratings

The average analyst rating for Aytu BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	2	2	2	2	2	2
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Naz Rahman Maxim Group	Maxim Group	Buy Reiterates $7	Buy	Reiterates	$7	+225.58%	May 15, 2026
Thomas Flaten Lake Street	Lake Street	Buy Maintains $7	Buy	Maintains	$7	+225.58%	May 14, 2026
Edward Woo Ascendiant	Ascendiant	Buy Maintains $13 → $14	Buy	Maintains	$13 → $14	+551.16%	Mar 12, 2026

Financial Forecast

Revenue This Year

53.75M

from 66.38M

-19.03%

from 66.38M

Revenue Next Year

70.63M

from 53.75M

31.41%

from 53.75M

EPS This Year

-1.14

from -0.11

EPS Next Year

-0.08

from -1.14

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Jun 30, 2021	Jun 30, 2022	Jun 30, 2023	Jun 30, 2024	Jun 30, 2025	Jun 30, 2026
Revenue	65.63M	96.67M	73.80M	65.18M	66.38M	53.75M
Revenue Growth	137.52%	47.29%	-23.66%	-11.68%	1.84%	-19.03%
Gross Profit	29.20M	50.28M	52.23M	49.05M	45.83M	34.40M
Gross Margin	44.49%	52.02%	70.77%	75.26%	69.04%	64.00%
Operating Income	-38.24M	-38.10M	-5.21M	565.00K	2.54M	-12.14M
Net Income	-58.29M	-108.78M	-17.05M	-15.84M	-13.56M	-19.45M
EPS	-	-	-	-	-0.11	-1.14
Free Cash Flow	15.64M	-17.72M	5.56M	3.92M	-9.49M	12.36M
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	54.8M
Avg	53.7M
Low	53.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	-17.4%
Avg	-19.0%
Low	-20.1%

EPS Forecast

EPS	2026	2027	2028
High	-1.02
Avg	-1.14
Low	-1.25

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-